Roadblocks ahead on the WHO Roadmap on Access to Medicines and Vaccines?

By Katy Athersuch [1] and Thiru Balasubramaniam In May 2018, the World Health Assembly (WHA) adopted decision WHA71(8) requesting WHO’s Director-General to “elaborate a roadmap, in consultation with Member States, outlining the programming of WHO’s work on access to medicines… Continue Reading

WHA71: KEI intervention on the Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018

At the 71st World Health Assembly, KEI will deliver the following intervention regarding the Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018. 11.7 Preparation for… Continue Reading

WHO donors in 2017 – US, Gates Foundation, UK, World Bank, GAVI, Germany and the European Commission: Setting the Agenda for Global Health?

In advance of the 71st World Health Assembly (21 May 2018 – 26 May 2018), the World Health Organization (WHO) published a document (A71/INF./2, 19 April 2018) entitled, Voluntary contributions by fund and by contributor, 2017. Total voluntary contributions to… Continue Reading

Negotiations on R&D funding agreements

1994 1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, May 12. A discussion of how R&D mandates can ensure innovation does not suffer when prices lowering policies are embraced. 1996 1996: Comments… Continue Reading

EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines

On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”

In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:

Continue Reading

KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and Development

Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34

My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.

I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.

We have suggestions for some changes in the discussion, to move things forward.

Continue Reading

The Blur Banff proposal

Notes on the Blur Banff proposal* KEI Research Note 2013:1 February 1, 2013 This is a brief note on the Blur/Banff proposal for a system of decentralized decision making and competitive intermediaries to provide money to support recorded music that… Continue Reading